The peer-reviewed data on recombinant BET is here, and it says that recombinant BET methods are inferior to LAL. The European Journal of Pharmaceutical Sciences published new research that challenged the recombinant alternatives to the LAL method, and the results from this study demonstrated that all recombinant products have a propensity to underpredict endotoxin activity when compared to gold standard, LAL. 

Still considering evaluating an alternative endotoxin testing method? View the peer-reviewed research article, Evaluation of Limulus Amebocyte Lysate and Recombinant Endotoxin Alternative Assays for an Assessment of Endotoxin Detection Specificity.